基本信息
views: 16
Career Trajectory
Bio
Dr. Rahbari-Oskoui, MD, MS is a Professor of Medicine and the director of Cystic Kidney Diseases Clinic at Emory University. He attended medical school at Université de Bordeaux in France and obtained his MD (magna cum laude) in 1997 after completing a residency program in general medicine and partial nephrology training at the same institution. After his move to France, he completed his Internal Medicine residency at St. Vincent Hospital -Columbia University College of Physicians and Surgeons from 2000-2003 and his academic track fellowship in nephrology at Emory University from 2003-2006. He joined the faculty at Emory University School of Medicine’s Division of Renal Medicine in July of 2006 at the rank of instructor. He was promoted to Assistant professor of medicine in 2007, Associate professor of medicine in 2014 and Professor of Medicine in 2020. During this time, he also obtained a Master of Science in Clinical Research (MSCR) degree from Emory University.
Dr. Rahbari is a diplomate of the American Board of Internal Medicine and is board-certified in nephrology.
His areas of expertise are cystic diseases of the kidneys (most particularly ADPKD), inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in renal diseases. He has co-authored more than 70 original manuscripts, review articles, and textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease.
He is a Fellow of the American Society of Nephrology, a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.
He is a clinical and translational invesitigator and has been involved in many landmark trials and observational cohorts: HALT-PKD trials, TEMPO and REPRISE trials, the SPRINT trail, The CRISP study (Consortium for Radiologic Imaging of Polycystic Kidney disease), the MUSE trial, the Melatonin in night-time blood pressure in African-Americans (MAP) trials, the EMPA-Kidney trial, the pharmacogenomics of Essential Hypertension (PEAR trial) , the STAGE-PKD trial, the Tesevatinib in ADPKD trial and the FALCON trial.
Dr. Rahbari-Oskoui has won many teaching awards at Emory University for his excellence in teaching to the residents and fellows.
Research Interests
Papers共 54 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYno. 2 (2024): 213-223
Alan S. Yu, Aaron Cohen, Erin Ables, Doug Landsittel,Vicente E. Torres,Fouad T. Chebib,Arlene B. Chapman,Peter C. Harris,Michal Mrug,Frederic F. Rahbari-Oskoui,Kyongtae T. Bae,Stephanie Dickinson,
Journal of the American Society of Nephrologyno. 11S (2023): 209-209
Kidney Internationalno. 2 (2023): 334-342
Clinical journal of the American Society of Nephrology : CJASNno. 5 (2023): 664-682
Neera K. Dahl,Fouad T. Chebib,Frederic F. Rahbari-Oskoui,Hina Japes, Huan Jiang, LaRee A. Tracy, Linda Mccormick, Katherine Maringer, Ronald D. Perrone, Ali Nourbakhsh
Journal of the American Society of Nephrologyno. 11S (2022): 161-162
Kidney360 (2022)
Kidney360no. 7 (2022): 1253-1262
Journal of the American Society of Nephrologyno. 10S (2021): 282-282
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn